Leveraging continuous manufacturing technologies based on current resources and future goals
Unique training courses designed around real-life situations, with hands-on access to enabling technologies.
Pall Corporation is partnering with the BioFactory Competence Center (BCC) in Fribourg, Switzerland to launch new training courses in early 2018 focused on continuous bioprocessing advances. The courses will detail the state of the industry and the advantages and practical implications of transitioning from batch to semi- or fully continuous bioprocess methodologies. Pall Life Sciences’ Cadence platform technologies will be featured for hands-on training. Registration for standard sessions will be available through the BCC beginning in December; custom sessions are available upon request.
The upcoming courses will highlight key advantages of integrated continuous bioprocessing, and how best to leverage semi- or fully continuous manufacturing technologies based on current resources and future goals. The practical sessions will feature Pall Life Sciences’ process development scale technologies, including the Cadence Acoustic Separator for continuous clarification and separation, the Cadence BioSMB PD system for multi-column chromatography, and the Cadence Inline Concentrator for continuous concentration at various process steps.
“As drug manufacturers look to shift from batch to continuous processing for both small and large molecule drugs, information-sharing and continued education have become key drivers of advancement,” said Peter Levison, Senior Marketing Director of Downstream Processing at Pall Corporation. “These unique training courses have been designed around real-life situations, with hands-on access to enabling technologies, and we are proud to support them.”
In addition to the new courses, plans exist to build a dedicated continuous bioprocessing facility in Fribourg for education on, and application of, continuous bioprocessing technologies. The facility will also feature Pall Cadence platform technologies.
“The BCC launched in January 2016 to deliver theoretical and practical biopharmaceutical industry training on everything from basic aseptic techniques to more detailed applications focused training from upstream to downstream processing, covering cell culture, cell separation, chromatography and concentration, comparing single-use vs. traditional approaches,” stated Ian Marison, CEO and co-founder of the BCC. “As industry interest grows in the advantages of continuous bioprocessing, we felt it necessary to introduce specialized training for successfully navigating this next-generation of drug making.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance